| Literature DB >> 27266871 |
Eun Young Heo1, Sue Shin2, Hee Soon Chung3, Yun-Jeong Jeong4, So Hee Oh5, Deog Kyeom Kim3.
Abstract
BACKGROUND: Pneumonia is a primary cause of morbidity and mortality in infectious disease, and increasing antimicrobial resistance has raised concerns of treatment failure. Therefore, we evaluated the value of a blood culture bottle for bronchoalveolar lavage (BAL) samples on pathogen identification and on treatment modification in patients with pneumonia.Entities:
Keywords: Blood culture bottle; Bronchoalveolar lavage; Pneumonia
Mesh:
Substances:
Year: 2016 PMID: 27266871 PMCID: PMC4895882 DOI: 10.1186/s12879-016-1591-2
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Definitions of HAP, VAP, and HCAP (7)
| • HAP (hospital-acquired pneumonia) | |
| Pneumonia that occurs ≥48 h from time of admission | |
| • VAP (ventilator-associated pneumonia) | |
| Pneumonia that arises 48 to 72 h after endotracheal intubation | |
| • HCAP (healthcare-associated pneumonia) | |
| Prior hospitalization ≥2 days (within 90 days) | |
| Resided in nursing home or long-term care facility | |
| Received recent IV antibiotics, chemotherapy, or wound care (within 30 days) | |
| Attended a hospital or hemodialysis clinic |
Baseline characteristics of patients (N = 39)
| Variables | N (%) |
|---|---|
| Age (years) | |
| Median (range) | 70.5 (37–93) |
| Male | 27 (69.2) |
| Category of pneumonia | |
| CAP | 21 (53.8) |
| HCAP | 6 (15.4) |
| HAP & VAP | 12 (30.8) |
| Comorbidities | |
| Diabetes mellitus | 5 (12.5) |
| Solid organ malignancy | 11 (27.5) |
| Hematologic malignancy | 2 (5) |
| Chronic respiratory disease | 8 (20.5) |
| HIV infection | 1 (2.6) |
| Antibiotics started on admission | 38 (97.4) |
| Antibiotics started within 24 h before BAL | 13 (33.3) |
| Duration of antibiotics before bronchoscopy (days), mean ± SD | 5.8 ± 6.4 |
| Leukocytes (per mm3), mean ± SD | 11,226 ± 5056 |
| C-reactive protein (mg/dL), mean ± SD | 11.74 ± 8.24 |
| Pneumonia outcome | |
| Improved | 31 (77.5) |
| Transferred out | 1 (2.5) |
| Died | 7 (17.5) |
Concordance between sputum culture, BAL quantitative culture, and BAL culture using blood culture bottles
| Sputum culture | BAL quantitative culture | BAL blood bottle culture | |
|---|---|---|---|
|
| 4 (1: ESBL) | ||
|
| 1 | 5 (2: ESBL) | |
|
| 5 (3: MRSA) | 2 (2: MRSA) | 9 (7:MRSA) |
| Viridans streptococci | 9 (1: penicillin and other beta-lactam resistant) | ||
|
| 1 | 1 (1: penicillin and other beta-lactam resistant) | |
|
| 2 (2: IRAB) | 2 (2: IRAB) | 7 (6: IRAB) |
|
| 1 | 2 (2: ESBL) | |
|
| 2 | 1 | |
| Others | MRCNS, 2 | 2 |
ESBL extended spectrum beta-lactamase, IRAB imipenem-resistant Acinetobacter baumannii, MRSA methicillin-resistant Staphylococcus aureus, MRCNS methicillin-resistant coagulase negative staphylococci
Characteristics of patients that changed antibiotic treatments according to the BAL fluid blood culture bottle results
| Patient | Pneumonia category | Conventional | BAL fluid blood culture bottle | Antibiotics before BAL | Antibiotics after BAL | Outcome |
|---|---|---|---|---|---|---|
| 1 | HAP | MRCNS |
| ceftazidime, vancomycin | cefepime + amikacin | improved |
| 2 | CAP |
|
| meropenem | ceftazidime, ciprofloxacin | death |
| 3 | HAP | throat normal flora |
| meropenem | colistin | death |
| 4 | CAP | none | MRSA, | ampicillin/sulbactam | ampicillin, sulbactam, vancomycin | improved |
| 5 | CAP | none | Viridans streptococci (penicillin: I, clindamycin: R) | ceftriaxone, clindamycin | vancomycin | improved |
| 6 | HCAP | none | Viridans streptococci (penicillin: R), MRCNS | ceftriaxone, azithromycin | tazocin, levofloxacin | improved |
| 7 | HCAP | none |
| piperacillin + tazobactam, meropenem | colistin | improved |
| 8 | CAP | none |
| ceftriaxone | levofloxacin | improved |
ESBL extended spectrum beta-lactamase, IRAB imipenem-resistant Acinetobacter baumannii, MRSA methicillin-resistant Staphylococcus aureus, MRCNS methicillin-resistant coagulase negative staphylococci